scholarly journals Leptomeningeal Disease as an Initial Presenting Manifestation in Breast Cancer

Cureus ◽  
2021 ◽  
Author(s):  
Jasmine Shrestha ◽  
Asis Shrestha ◽  
Pratul Karki ◽  
Ajay Dhakal
Keyword(s):  
Breast Cancer ◽  
Leptomeningeal Disease

scholarly journals High-dose intravenous methotrexate in the management of breast cancer with leptomeningeal disease: Case series and review of the literature

2019 ◽  
Vol 12 (4) ◽  
pp. 189-193 ◽  
Author(s):  
Jonathan T. Kapke ◽  
Robert J. Schneidewend ◽  
Zeeshan A. Jawa ◽  
Chiang-Ching Huang ◽  
Jennifer M. Connelly ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Series ◽  
Leptomeningeal Disease ◽  
High Dose ◽  
Review Of The Literature ◽  
Disease Case

Leptomeningeal disease following stereotactic radiosurgery for brain metastases from breast cancer

2015 ◽  
Vol 124 (3) ◽  
pp. 421-427 ◽  
Author(s):  
Daniel M. Trifiletti ◽  
Kara D. Romano ◽  
Zhiyuan Xu ◽  
Kelli A. Reardon ◽  
Jason Sheehan
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Stereotactic Radiosurgery ◽  
Leptomeningeal Disease

scholarly journals Endocrine therapy for the treatment of leptomeningeal carcinomatosis in luminal breast cancer: a comprehensive review

CNS Oncology ◽  
2020 ◽  
Vol 9 (4) ◽  
pp. CNS65
Author(s):  
Leonor Fernandes ◽  
Leonor Vasconcelos de Matos ◽  
Débora Cardoso ◽  
Marlene Saraiva ◽  
Renata Medeiros-Mirra ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Leptomeningeal Carcinomatosis ◽  
Luminal Breast Cancer ◽  
Leptomeningeal Disease ◽  
Targeted Agents ◽  
Published Evidence ◽  
Cns Activity ◽  
Evidenced Based

Leptomeningeal disease (LMD) represents a devastating complication of advanced breast cancer (ABC), with survival of <5 months with multimodal treatment. The role of endocrine therapy (ET), due to its favorable toxicity profile and first-line indication in luminal ABC, appears promising in the setting of LMD, where symptom stabilization and quality-of-life preservation are the main goals; however, evidenced-based data are lacking. We conducted a thorough review of published evidence, aiming to investigate the role of ET in LMD treatment in luminal ABC. Twenty-one of 342 articles, evaluating 1302 patients, met inclusion criteria. ET use was rarely reported. New targeted agents show CNS activity. Research is lacking on the role of ET and targeted agents in BC-LMD treatment.

scholarly journals 56. TUMOR-HOMING STEM CELL THERAPY INHIBITS THE PROGRESSION OF BREAST CANCER LEPTOMENINGEAL CARCINOMATOSIS

2020 ◽  
Vol 2 (Supplement_2) ◽  
pp. ii11-ii12
Author(s):  
Wulin Jiang ◽  
Alain Valdivia ◽  
Alison Mercer-Smith ◽  
Carey Anders ◽  
Shawn Hingtgen
Keyword(s):  
Breast Cancer ◽  
Spinal Cord ◽  
Cancer Cells ◽  
Limit Of Detection ◽  
Human Fibroblasts ◽  
Leptomeningeal Carcinomatosis ◽  
Leptomeningeal Disease ◽  
Breast Cancer Patients ◽  
Tumor Homing ◽  
The Brain

Abstract INTRODUCTION Leptomeningeal carcinomatosis remains one of the most lethal forms of central nervous system metastasis, with a median survival of only 4 months. Effective new therapies are urgently needed to treat this highly aggressive cancer. In this study, we used models of both prophylactic and established leptomeningeal disease to investigate the efficacy of engineered tumor-homing neural stem cells (NSCs) therapy for breast cancer leptomeningeal carcinomatosis. METHODS Personalized NSC carriers were created using Sox2 overexpression to transdifferentiate human fibroblasts into induced NSCs (iNSCs) that home to cancer cells and carry therapeutic agents to induce tumor kill. Leptomeningeal models were created by engineering MDA-MB231-Br human breast cancer cells with fluorescent and bioluminescent reporters, then using intracisternal injection to inoculate Nude mice with the tumor cells. iNSC therapy was evaluated by infusing iNSCs releasing the pro-apoptotic agent TRAIL into the lateral ventricle of mice either 1 week prior to or 3 days after tumor inoculation for prophylactic or established tumor treatment respectively. Tumor progression in the brain and spinal cord was monitored by serial bioluminescence imaging (BLI). RESULTS Serial BLI showed that intracerebroventricular (ICV) iNSC-TRAIL therapy reduced the volume of metastatic tumor burden 99.49% in the brain and 99.80% in the spine within 2 weeks post-infusion and extended survival from 24 to 42 days. Additionally, prophylactic iNSC-TRAIL therapy delivered ICV markedly delayed tumor development, with tumors in the brain remaining &gt;1000-fold smaller than control through 1-month post-treatment, below the limit of detection in the spinal cord through 1 month, and eliminating mortality through 50 days post-therapy. CONCLUSION These data suggest that iNSC therapy could be a promising treatment option for breast cancer patients with leptomeningeal carcinomatosis.

Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience

The Breast ◽  
2017 ◽  
Vol 36 ◽  
pp. 54-59 ◽  
Author(s):  
Belinda Kingston ◽  
Hamzeh Kayhanian ◽  
Chloe Brooks ◽  
Nicola Cox ◽  
Narda Chaabouni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Leptomeningeal Disease ◽  
Single Centre ◽  
Single Centre Experience

Leptomeningeal disease and breast cancer: Relationship of outcome and subtype.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 601-601
Author(s):  
Sausan Abouharb ◽  
Joe Ensor ◽  
Monica Elena Loghin ◽  
Ruth Katz ◽  
Ana M. Gonzalez-Angulo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Proportional Hazards ◽  
Treatment Strategies ◽  
Continuous Variable ◽  
Cox Proportional Hazards ◽  
Intrathecal Therapy ◽  
Leptomeningeal Disease ◽  
Tumor Subtype ◽  
Dismal Prognosis ◽  
Significant Difference

601 Background: Breast cancer (BC) is one of the most common tumors to involve the leptomeninges. Outcome of leptomeningeal disease (LMD) across BC subtypes is not well documented. We aimed to characterize clinical features and outcomes of LMD based on BC subtypes. Methods: We retrospectively reviewed medical records of patients diagnosed with LMD from BC (1997 to 2012). All patients had BC. Cases of LMD were based on the presence of neoplastic cells on cerebrospinal fluid examination and/or evidence of LMD by imaging studies. Survival was estimated by the Kaplan-Meier method and significant differences in survival were determined by Cox proportional hazards or log-rank tests. Results: 232 patients were included, 189 of them had available tumor subtype classified as: hormone receptor positive (HR+) BC N=67 (35.5%), human epidermal growth factor receptor 2 positive (HER2+) N=55 (29%), and 67 (35.5%) triple-negative BC (TNBC). Median age at diagnosis of LMD was 49.7 years. (Range 24-89). Median overall survival (OS) from LMD diagnosis across all subtypes was 3.1 months (95% CI, 2.5 to 3.7). Median OS correlated with BC subtype: 3.7 months (95% CI: 2.4, 6.0) in HR+, 4.0 months (95% CI: 2.6, 6.9) in HER2+, and 2.2 months (95% CI: 1.5, 3.0) in TNBC, (p=0.0002). There was an 11.4% chance a patient diagnosed with LMD would survive 1 year and the chance of surviving at least 3 years was 1.3%. When age was used as a continuous variable, older age was associated with worse outcome (p<0.0001). Patients with HER2+ BC and LMD were more likely to have received systemic therapy (ST) (70%), compared to HR+ (41%) and TNBC (41%) (p=0.002). 38% of patients with HER2+ BC received HER2 directed therapy. There was no difference in the use of intrathecal therapy (IT) (52%) across subtypes (p=0.3). Use of IT therapy (p<0.0001) and ST (p<0.0001) were both associated with improved age-adjusted OS. After adjusting for age, ST, there was no difference in OS between patients with HR+ and HER2+ BC (p =0.14), but a significant difference remained between TNBC and HER2+ BC (p < 0.0001). Conclusions: LMD carries a dismal prognosis. Our data shows that OS correlates with tumor subtype. Patients with TNBC had a significantly shorter OS compared to patients with HER2+ BC. New treatment strategies are needed.

scholarly journals Complete Radiologic Response and Long-Term Survival With Use of Systemic High-Dose Methotrexate for Breast Cancer–Associated Leptomeningeal Disease

2012 ◽  
Vol 12 (6) ◽  
pp. 445-449 ◽  
Author(s):  
Cesar A. Santa-Maria ◽  
Ashley Cimino-Mathews ◽  
Kendall F. Moseley ◽  
Antonio C. Wolff ◽  
Jaishri O. Blakeley ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Leptomeningeal Disease ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Term Survival ◽  
Long Term Survival ◽  
Dose Methotrexate
Sign in / Sign up

Export Citation Format

Share Document